Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2019Author
Kilickap, S.Demirci, U.
Buğdaycı, F.
Tural, D.
Korkmaz, T.
Paydas, S.
Cicin, İrfan
Seber, Selçuk
Metadata
Show full item recordAbstract
[No Abstract Available]
Volume
14Issue
10Collections
- Tıp Fakültesi Koleksiyonu [2104]
- WoS İndeksli Yayınlar Koleksiyonu [4789]